Regorafenib Monotherapy as Second-line Treatment of Patients With RAS-mutant Advanced Colorectal Cancer
收藏NIAID Data Ecosystem2026-03-09 收录
下载链接：
https://www.omicsdi.org/dataset/ecrin-mdr-crc/2203440
下载链接
链接失效反馈官方服务：
资源简介：
The purpose of this study is to purpose of this study is to assess if regorafenib is active enough, in terms of 6-month progression-free rate, to warrant further comparative studies in patients with RAS-mutant advanced colorectal cancer who have progressed after first-line oxaliplatin-based chemotherapy plus bevacizumab.
创建时间：
2015-11-15
